Shanghai Auzone Biological Technology
Privately held: no public share price · China
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | oxidative stressSmall molecule | Alzheimer's DiseaseAcute Ischemic Stroke |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
October 2028 (1)
Est. primary completion 2028-10-23 · NCT07252440 · CT.gov ↗
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
31 July 2025Filing acceptedEdaravone tablets (TTYP01)NMPA accepts the marketing application for edaravone tablets (TTYP01) in acute ischemic stroke (Huadong Medicine notice 2025-07-31)
CN, NMPA · Shanghai Auzone Biological Technology · Source ↗
Financial reports
No financial reports recorded.